Framebased-Frameless_DV_2017_final.pptx

944 / 1578

• No classic RILD
• Decline in C-P class by 2 points
in 29% at 3 mts and 6% at 12
mts
• Liver failure (gr 5) in 5 pts 5%
• Cholangitis (gr 5) 1 pt
• Duodenal bleed (gr 5) 1 pt
Morbidity in two prospective SBRT trials on
HCC
Phase I (n=50) Cardenes et al Clin Transl Oncol 2010; 12:218
Phase II (n=52) Tse et al JCO 2008; 26: 3911
All pts C-P 6 treated with NTCP-based dose-prescription (<10% RILD)
Classic RILD
(without underlying liver disease)
• Fatigue
• Abdominal pain
• Increased abdominal girth
• Hepatomegaly
• Anicteric ascites
• Isolated elevation of alkaline phosphatase
Non-classic RILD
(with underlying liver disease)
• Jaundice
• Markedly elevated serum transaminase Median Dliver-CTV
• Failure 18.1 Gy
• No failure 14.4 Gy
N=102